Several changes to protocols have been reported by Celgene with regard to its midstage trial to test the efficacy of its chimeric antigen receptor T-cell therapy bb2121 to treat patients with relapsed or refractory multiple myeloma. Amended protocols include raising the dosage to be administered and increasing the number of participants to 140.
Celgene amends protocols for midstage study of CAR T candidate bb2121
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.